- Home
- SURG vs ABOS Comparison
SURG vs ABOS Comparison
Compare SURG & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SURG
- ABOS
- Stock Information
- Founded
- SURG 2006
- ABOS 1996
- Country
- SURG United States
- ABOS United States
- Employees
- SURG N/A
- ABOS N/A
- Industry
- SURG Advertising
- ABOS Biotechnology: Pharmaceutical Preparations
- Sector
- SURG Consumer Discretionary
- ABOS Health Care
- Exchange
- SURG Nasdaq
- ABOS Nasdaq
- Market Cap
- SURG 56.5M
- ABOS 60.6M
- IPO Year
- SURG N/A
- ABOS 2021
- Fundamental
- Price
- SURG $2.70
- ABOS $1.20
- Analyst Decision
- SURG Strong Buy
- ABOS Strong Buy
- Analyst Count
- SURG 1
- ABOS 4
- Target Price
- SURG $9.00
- ABOS $6.50
- AVG Volume (30 Days)
- SURG 84.4K
- ABOS 304.2K
- Earning Date
- SURG 08-12-2025
- ABOS 08-12-2025
- Dividend Yield
- SURG N/A
- ABOS N/A
- EPS Growth
- SURG N/A
- ABOS N/A
- EPS
- SURG N/A
- ABOS N/A
- Revenue
- SURG $40,029,467.00
- ABOS N/A
- Revenue This Year
- SURG $124.78
- ABOS N/A
- Revenue Next Year
- SURG $49.21
- ABOS N/A
- P/E Ratio
- SURG N/A
- ABOS N/A
- Revenue Growth
- SURG N/A
- ABOS N/A
- 52 Week Low
- SURG $1.05
- ABOS $0.86
- 52 Week High
- SURG $3.52
- ABOS $3.60
- Technical
- Relative Strength Index (RSI)
- SURG 47.31
- ABOS 53.50
- Support Level
- SURG $2.70
- ABOS $1.05
- Resistance Level
- SURG $2.95
- ABOS $1.31
- Average True Range (ATR)
- SURG 0.17
- ABOS 0.09
- MACD
- SURG -0.03
- ABOS 0.01
- Stochastic Oscillator
- SURG 27.91
- ABOS 48.61
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; and Others. It generates the majority of its revenue from the Mobile Virtual Network Operators segment.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.